Unilife Corp. has signed a customization and commercial supply agreement with a U.S. pharmaceutical company for the EZMix dual-chamber syringe. Unilife will supply a customized device from its EZMix platform of delivery systems for use with a lyophilized drug that requires mixing at the time of injection. The drug, which is a proprietary version of an approved therapy, is entering late-stage development.   Unilife anticipates as much as $110 million in revenue during the 15-year agreement, based...